Abstract |
The MGTX trial is the first prospective, randomized clinical trial that aims to evaluate the impact of extended transsternal thymectomy on myasthenic symptoms, prednisone requirements, and quality of life in patients with nonthymomatous, anti- acetylcholine receptor autoantibody-positive myasthenia gravis (MG). Here, we give an overview of the rationale of thymectomy and the standardized macroscopic and histopathological work-up of thymectomy specimens as fixed in MGTX standard operating procedures, including the grading of thymic lymphofollicular hyperplasia and the morphometric strategy to assess thymic involution.
|
Authors | Alexander Marx, Frederik Pfister, Berthold Schalke, Wilfred Nix, Philipp Ströbel |
Journal | Annals of the New York Academy of Sciences
(Ann N Y Acad Sci)
Vol. 1275
Pg. 92-100
(Dec 2012)
ISSN: 1749-6632 [Electronic] United States |
PMID | 23278583
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2012 New York Academy of Sciences. |
Topics |
- Humans
- Immunohistochemistry
- Myasthenia Gravis
(physiopathology, surgery)
- Prospective Studies
- Thymus Gland
(pathology, surgery)
|